Success.ai’s Pharma Data for the Global Pharmaceutical Industry provides a robust dataset tailored for businesses looking to connect with pharmaceutical companies, decision-makers, and key stakeholders worldwide. Covering pharmaceutical manufacturers, research organizations, biotech firms, and distributors, this dataset offers verified SIC codes, firmographic details, and contact information for executives and operational leads.

With access to over 170 million verified professional profiles and 30 million company profiles, Success.ai ensures your outreach, market research, and business development strategies are driven by reliable, continuously updated, and AI-validated data. Supported by our Best Price Guarantee, this solution is essential for navigating the competitive global pharmaceutical landscape.

Why Choose Success.ai’s Pharma Data?

1. Verified Contact Data for Precision Outreach

   • Access verified work emails, phone numbers, and LinkedIn profiles of pharmaceutical executives, R&D leads, compliance officers, and procurement managers.
   • AI-driven validation ensures 99% accuracy, optimizing your campaigns and improving communication efficiency.

2. Comprehensive Coverage of the Global Pharmaceutical Sector

   • Includes profiles of pharmaceutical companies, biotech firms, contract manufacturing organizations (CMOs), and distributors across North America, Europe, Asia, and other major markets.
   • Gain insights into regional pharmaceutical trends, product pipelines, and market dynamics unique to global markets.

3. Continuously Updated Datasets

   • Real-time updates reflect leadership changes, mergers, product launches, and regulatory compliance shifts.
   • Stay aligned with the fast-paced pharmaceutical industry to capitalize on emerging opportunities and maintain relevance.

4. Ethical and Compliant

   • Adheres to GDPR, CCPA, and other global privacy regulations, ensuring responsible use of data and compliance with legal standards.

Data Highlights:

• 170M+ Verified Professional Profiles: Engage with decision-makers, R&D specialists, and operational leaders in the pharmaceutical industry worldwide.
• 30M Company Profiles: Access detailed firmographic data, including company sizes, revenue ranges, and geographic footprints.
• Verified SIC Codes: Understand industry classifications and product specializations to refine your targeting strategies.
• Leadership Contact Details: Connect with CEOs, COOs, medical directors, and regulatory managers influencing pharmaceutical operations.

Key Features of the Dataset:

1. Decision-Maker Profiles in Pharmaceuticals

   • Identify and engage with professionals overseeing R&D, clinical trials, supply chains, and regulatory compliance.
   • Target leaders responsible for drug development, vendor selection, and market entry strategies.

2. Advanced Filters for Precision Targeting

   • Filter companies by industry segment (biotech, generic pharmaceuticals, vaccines), geographic location, or revenue size.
   • Tailor campaigns to align with specific needs such as drug pipeline acceleration, production scaling, or market expansion.

3. SIC Codes and Firmographic Insights

   • Access verified SIC codes and detailed company profiles to understand market focus, operational scale, and specialization areas.
   • Use firmographic data to prioritize high-value targets and align product offerings with market demands.

4. AI-Driven Enrichment

   • Profiles enriched with actionable data allow for personalized messaging, highlight unique value propositions, and improve engagement outcomes with pharmaceutical stakeholders.

Strategic Use Cases:

1. Sales and Lead Generation

   • Offer technology solutions, research tools, or contract services to pharmaceutical manufacturers, R&D facilities, and distribution networks.
   • Build relationships with procurement teams and compliance officers responsible for vendor approvals and operational excellence.

2. Market Research and Product Development

   • Analyze global pharmaceutical trends, drug approval patterns, and regulatory frameworks to guide product innovation and market entry strategies.
   • Identify high-growth regions and emerging therapeutic areas to focus your resources effectively.

3. Partnership and Supply Chain Development

   • Connect with pharmaceutical companies seeking contract manufacturing, raw material sourcing, or distribution partnerships.
   • Foster alliances that streamline production, ensure quality, and accelerate time-to-market.

4. Regulatory Compliance and Risk Mitigation

   • Engage with regulatory officers and compliance managers overseeing adherence to local and international pharmaceutical standards.
   • Present solutions for documentation, reporting, and risk management to ensure compliance and operational efficiency.

Why Choose Success.ai?

1. Best Price Guarantee
   ...

Discharges from pharmaceutical manufacturing facilities (PMFs) previously have been identified as important sources of pharmaceuticals to the environment. Yet few studies are available to establish the influence of PMFs to the pharmaceutical source contribution to wastewater treatment plants (WWTPs) and waterways at the national scale. Consequently, a national network of 13 WWTPs receiving PMF discharges and 7 WWTPs with no PMF input (controls) were selected from across the United States to assess the influence of PMF input for a diverse suite of pharmaceuticals being formulated for a range of WWTP sizes. WWTP effluent samples were collected and analyzed for 120 pharmaceuticals and pharmaceutical degradates. Of these, 33 pharmaceuticals had concentrations significantly higher in PMF-influenced effluent (maximum 555,000 nanograms per liter) compared to effluent from control sites (maximum 175 nanograms per liter). Concentrations in PMF discharges are episodic and indicate that production activities can vary substantially over relatively short (several months) periods and the potential to rapidly transition to other pharmaceutical products. Results show that PMFs are an important, national-scale source of pharmaceuticals to the environment. Additional research is needed to determine if the observed elevated pharmaceutical concentrations discharged from PMF-influenced WWTPs translate to an increase in adverse environmental effects in corresponding waterways.

This dataset contains the metadata records about research products (research literature, data, software, other types of research products) with funding information available in the OpenAIRE Graph produced on July 2024.Records are grouped by funder in a dedicated archive file (

fundRef contains the following funders

100007490 Bausch and Lomb Ireland

100007630 College of Engineering and Informatics, National University of Ireland, Galway

100007731 Endo International

100007819 Allergan

100008099 Food Safety Authority of Ireland

100008124 Department of Jobs, Enterprise and Innovation

100008303 Department for Economics, Northern Ireland

100009098 Department of Foreign Affairs and Trade, Ireland

100009099 Irish Aid

100009770 National University of Ireland

100010399 European Society of Cataract and Refractive Surgeons

100010546 Deparment of Children and Youth Affairs, Ireland

100010547 Irish Youth Justice Service

100010993 Irish Nephrology Society

100011096 Jazz Pharmaceuticals

100011396 Irish College of General Practitioners

100012733 National Parks and Wildlife Service

100012734 Department for Culture, Heritage and the Gaeltacht, Ireland

100012754 Horizon Pharma

100012891 Medical Research Charities Group

100012919 Epilepsy Ireland

100012920 GLEN

100012921 Royal College of Surgeons in Ireland

100013029 Iris O'Brien Foundation

100013206 Food Institutional Research Measure

100013381 Irish Phytochemical Food Network

100013433 Transport Infrastructure Ireland

100013917 Society for Musicology in Ireland

100014251 Humanities in the European Research Area

100014364 National Children's Research Centre

100014384 Amarin Corporation

100014902 Irish Association for Cancer Research

100015023 Ireland Funds

100015278 Pfizer Healthcare Ireland

100015319 Sport Ireland Institute

100015442 Global Brain Health Institute

100015992 St. Luke's Institute of Cancer Research

100017144 Shell E and P Ireland

100017897 Friedreich’s Ataxia Research Alliance Ireland

100018064 Department of Tourism, Culture, Arts, Gaeltacht, Sport and Media

100018172 Department of the Environment, Climate and Communications

100018175 Dairy Processing Technology Centre

100018270 Health Service Executive

100018529 Alkermes

100018542 Irish Endocrine Society

100018754 An Roinn Sláinte

100019428 Nabriva Therapeutics

100019637 Horizon Therapeutics

100020174 Health Research Charities Ireland

100020202 UCD Foundation

100020233 Ireland Canada University Foundation

100022895 Health Research Institute, University of Limerick

100022943 National Cancer Registry Ireland

501100001581 Arts Council of Ireland

501100001582 Centre for Ageing Research and Development in Ireland

501100001583 Cystinosis Foundation Ireland

501100001584 Department of Agriculture, Food and the Marine, Ireland

501100001586 Department of Education and Skills, Ireland

501100001587 Economic and Social Research Institute

501100001588 Enterprise Ireland

501100001591 Heritage Council

501100001592 Higher Education Authority

501100001593 Irish Cancer Society

501100001594 Irish Heart Foundation

501100001595 Irish Hospice Foundation

501100001596 Irish Research Council for Science, Engineering and Technology

501100001598 Mental Health Commission

501100001599 National Council for Forest Research and Development

501100001600 Research and Education Foundation, Sligo General Hospital

501100001601 Royal Irish Academy

501100001603 Sustainable Energy Authority of Ireland

501100001604 Teagasc

501100001627 Marine Institute

501100001628 Central Remedial Clinic

501100001629 Royal Dublin Society

501100001630 Dublin Institute for Advanced Studies

501100001631 University College Dublin

501100001633 National University of Ireland, Maynooth

501100001634 University of Galway

501100001635 University of Limerick

501100001636 University College Cork

501100001637 Trinity College Dublin

501100001638 Dublin City University

501100002736 Covidien

501100002755 Brennan and Company

501100002919 Cork Institute of Technology

501100002959 Dublin City Council

501100003036 Perrigo Company Charitable Foundation

501100003037 Elan

501100003496 HeyStaks Technologies

501100003553 Gaelic Athletic Association

501100003840 Irish Institute of Clinical Neuroscience

501100003956 Aspect Medical Systems

501100004162 Meath Foundation

501100004210 Our Lady's Children's Hospital, Crumlin

501100004321 Shire

501100004981 Athlone Institute of Technology

501100006518 Department of Communications, Energy and Natural Resources, Ireland

501100006553 Collaborative Centre for Applied Nanotechnology

501100006554 IDA Ireland

501100006759 CLARITY Centre for Sensor Web Technologies

501100009246 Technological University Dublin

501100009269 Programme of Competitive Forestry Research for Development

501100009315 Cystinosis Ireland

501100010808 Geological Survey of Ireland

501100011030 Alimentary Glycoscience Research Cluster

501100011031 Alimentary Health

501100011103 Rannís

501100011626 Energy Policy Research Centre, Economic and Social Research Institute

501100012354 Inland Fisheries Ireland

501100014384 X-Bolt Orthopaedics

501100014531 Physical Education and Sport Sciences Department, University of Limerick

501100014710 PrecisionBiotics Group

501100014745 APC Microbiome Institute

501100014826 ADAPT - Centre for Digital Content Technology

501100014827 Dormant Accounts Fund

501100017501 FotoNation

501100018641 Dairy Research Ireland

501100018839 Irish Centre for High-End Computing

501100019905 Galway University Foundation

501100020270 Advanced Materials and Bioengineering Research

501100020403 Irish Composites Centre

501100020425 Irish Thoracic Society

501100020570 College of Medicine, Nursing and Health Sciences, National University of Ireland, Galway

501100020871 Bernal Institute, University of Limerick

501100021102 Waterford Institute of Technology

501100021110 Irish MPS Society

501100021525 Insight SFI Research Centre for Data Analytics

501100021694 Elan Pharma International

501100021838 Royal College of Physicians of Ireland

501100022542 Breakthrough Cancer Research

501100022610 Breast Cancer Ireland

501100022728 Munster Technological University

501100023273 HRB Clinical Research Facility Galway

501100023551 Cystic Fibrosis Ireland

501100023970 Tyndall National Institute

501100024242 Synthesis and Solid State Pharmaceutical Centre

501100024313 Irish Rugby Football Union

501100024834 Tusla - Child and Family Agency

AKA Academy of Finland

ANR French National Research Agency (ANR)

ARC Australian Research Council (ARC)

ASAP Aligning Science Across Parkinson's

CHISTERA CHIST-ERA

CIHR Canadian Institutes of Health Research

EC_ERASMUS+ European Commission - Erasmus+ funding stream

EC_FP7 European Commission - FP7 funding stream

EC_H2020 European Commission - H2020 funding stream

EC_HE European Commission - HE funding stream

EEA European Environment Agency

EPA Environmental Protection Agency

FCT Fundação para a Ciência e a Tecnologia, I.P.

FWF Austrian Science Fund

HRB Health Research Board

HRZZ Croatian Science Foundation

INCA Institut National du Cancer

IRC Irish Research Council

IReL Irish Research eLibrary

MESTD Ministry of Education, Science and Technological Development of Republic of Serbia

MZOS TOADDNAME

NHMRC National Health and Medical Research Council (NHMRC)

NIH National Institutes of Health

NSERC Natural Sciences and Engineering Research Council of Canada

NSF National Science Foundation

NWO Netherlands Organisation for Scientific Research (NWO)

SFI Science Foundation Ireland

SNSF Swiss National Science Foundation

SSHRC Social Sciences and Humanities Research Council

TARA Tara Expeditions Foundation

TIBITAK Türkiye Bilimsel ve Teknolojik Araştırma Kurumu

UKRI UK Research and Innovation

WT Wellcome Trust

Each tar archive contains gzip files with one json record per line. Json records are compliant with the schema available at https://doi.org/10.5281/zenodo.13121069.

You can also search and browse this dataset (and more) in the OpenAIRE EXPLORE portal and via the OpenAIRE API.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year. DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit. The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.